The effects of omega-3 supplementation in gestational diabetes

The effects of omega-3 supplementation on inflammatory factors, oxidative stress biomarkers, pregnancy outcomes, and gene expression related to insulin, lipid, and inflammation in women with gestational diabetes

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170513033941N42

Enrollment

Registered

2018-12-19

Start date

2018-07-03

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gestational diabetes mellitus. Gestational diabetes mellitus

Interventions

Intervention 1: Intervention group: 2000 mg omega-3 daily (Barij Essence, Kashan, Iran) for 6 weeks orally. Intervention 2: Control group: Placebo capsule (Barij Essence, Kashan, Iran), for 6 weeks or

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with gestational diabetes mellitus. Individuals aged 18 to 40 years.

Exclusion criteria

Exclusion criteria: Exclusion criteria: Kidney or liver diseases Needing insulin therapy Pre-eclampsia Eclampsia Hypo and hyperthyroidism Smokers

Design outcomes

Primary

Measure	Time frame
Expressed levels of PPAR-? gene. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: PCR.	—

Secondary

Measure	Time frame
Hs-CRP. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Elisa kit.;Nitric oxide. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Spectrophotometry.;Expressed levels of LDLR gene. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: PCR.;Expressed levels of VEGF gene. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: PCR.;Expressed levels of TGF-ß gene. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: PCR.;Expressed levels of TNF gene. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: PCR.;Expressed levels of IL-1 gene. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: PCR.;Insulin. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Elisa kit.;Insulin resistance. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Calculation using HOMA formula.;Total cholesterol. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Enzymatic kit.;Triglycerides. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Enzymatic kit.;HDL. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Enzymatic kit.;LDL. Timepoi	—

Measure

Time frame

Hs-CRP. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Elisa kit.;Nitric oxide. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Spectrophotometry.;Malondialdehyde. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Spectrophotometry.;Glutathione. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Spectrophotometry.;Expressed levels of LDLR gene. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: PCR.;Expressed levels of VEGF gene. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: PCR.;Expressed levels of TGF-ß gene. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: PCR.;Expressed levels of TNF gene. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: PCR.;Expressed levels of IL-1 gene. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: PCR.;Insulin. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Elisa kit.;Insulin resistance. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Calculation using HOMA formula.;Total cholesterol. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Enzymatic kit.;Triglycerides. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Enzymatic kit.;HDL. Timepoint: At the beginning of the study and after 6 weeks of intervention. Method of measurement: Enzymatic kit.;LDL. Timepoi

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_z@kaums.ac.ir+98 31 5546 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026